{"disease":{"id":"multiple-myeloma-mm","name":"multiple myeloma mm"},"drugs":{"marketed":[{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 6 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 7 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 8 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 9 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 10 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 11 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 12 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 13 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 14 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 15 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 16 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 17 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07284890","indication_name":"Relapsed or Refractory Multiple Myeloma after at least 18 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07284890","generic_name":"pf-07284890","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."}],"pipeline":[],"offLabel":[],"totalMarketed":37,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05655546","title":"ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals","phase":"NA","overall_status":"TERMINATED","enrollment_count":2117,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":true},{"nct_id":"NCT05283993","title":"A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07428369","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1570,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT05361694","title":"Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT07222761","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":915,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06285318","title":"A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Janssen-Cilag Ltd.","has_results":false},{"nct_id":"NCT06383143","title":"Promoting Diagnosis and Management of AL in Italy (ProDigALIty)","phase":"","overall_status":"RECRUITING","enrollment_count":760,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT04721002","title":"Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)","phase":"","overall_status":"COMPLETED","enrollment_count":514,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07296627","title":"Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06615479","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":440,"lead_sponsor_name":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","has_results":false},{"nct_id":"NCT05730036","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07393282","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":270,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07477587","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":258,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT04659798","title":"A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice","phase":"","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07309497","title":"Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)","phase":"","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT06888856","title":"Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT04114084","title":"Sleep Apnea in Patients With MGUS and MM","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Michael Tomasson","has_results":false},{"nct_id":"NCT06767254","title":"A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT07305337","title":"Randomised Controlled Trial of Artificial Intelligence-assisted Health Education","phase":"NA","overall_status":"RECRUITING","enrollment_count":196,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT07236502","title":"Moving Foward With Myeloma (MFM)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT06980480","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":183,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07051850","title":"Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies","phase":"","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Sung-Soo Park","has_results":false},{"nct_id":"NCT07247097","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT07455851","title":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT04830046","title":"Covid-19 Vaccine Responsiveness in MM and Waldenstrom","phase":"","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06484829","title":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Chengdu Zenitar Biomedical Technology Co., Ltd","has_results":false},{"nct_id":"NCT07499128","title":"Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":136,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04824794","title":"GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":130,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT06838065","title":"Rehabilitation Management for Patients with Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT07446777","title":"FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT07087964","title":"Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT06140524","title":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07270263","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Medical University of Gdansk","has_results":false},{"nct_id":"NCT07448779","title":"Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06976476","title":"Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT07102706","title":"Phase I Trial of GR1803 Injection in Patients With RRMM","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05879757","title":"Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06645678","title":"Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"YOUNGIL KOH","has_results":false},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05673967","title":"Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07342179","title":"CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT05439538","title":"Serum NGAL IN Patients With Multiple Myeloma","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07333430","title":"Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT07214324","title":"Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT07088783","title":"Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Ozlem","has_results":false},{"nct_id":"NCT06103838","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}